Fenretinide therapy in prostate cancer: Effects on tissue and serum retinoid concentration

Journal of Clinical Oncology

Volumn 18, Issue 22, 2000, Pages 3804-3808

  Thaller, Christina ^a   Shalev, Moshe ^a   Frolov, Anna ^a   Eichele, Gregor ^a   Thompson, Timothy C ^a   Williams, Russel H ^a   Dillioglugil, Ozdal ^a   Kadmon, Dov ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; PLACEBO; RETINOIC ACID; RETINOID; RETINOL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BREAST; CANCER CHEMOTHERAPY; CANCER PREVENTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; TISSUE LEVEL;

EID: 0034669467     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.22.3804     Document Type: Article

References (30)

1. Cancer statistics 2000
2. Inhibition and reversal by beta-retinoic acid of hyperplasia induced in cultured mouse prostate tissue by 3-methylcholantrene or N-methyl-N-nitro-N-nitrosoguanidine
3. Inhibition of the effects of methylcholantrene on mouse prostate in organ culture by vitamin A and its analogs
4. 13-Cis retinoic acid in the treatment of oral leukoplakia
5. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis
6. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial
7. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
8. Prevention of second primary tumors with isotretinoin in patients with squamous-cell carcinoma of the head and neck: Long term follow-up
9. Abnormal level of retinoic acid in prostate cancer tissues
10. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system
11. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations
12. Multistage carcinogenesis induced by ras+myc oncogenes in a reconstituted organ cell
13. Elevated transforming growth factor-betal and beta3 mRNA levels are associated with ras+myc-induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression
14. Tolerability of the synthetic retinoid fenretinide (HPR)
15. Fresh tissue harvest for research from prostatectomy specimens
16. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome
17. Chromosomal translocation t(15,17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
18. The PML-RAR alpha fusion mRNA generated by the t(15,17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
19. Latent carcinoma of the prostate
20. Origin and development of carcinoma of the prostate
21. Probabilities of eventually developing or dying of cancer: United States 1985
22. Implication of cell kinetic changes during the progression of human prostatic cancer
23. N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells
24. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression
25. Fenretinide: Induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells
26. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide
27. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors and apoptosis-related genes in human prostate carcinoma cells
28. Anatomical barriers for antimicrobial agents
29. Cellular retinol-binding protein expression and breast cancer
30. Retinoids in cancer chemoprevention: Clinical trials with the synthetic analogue fenretinide